US Q2 Earnings Roundup: Coca-Cola Raises Guidance, Crane Soars 26%, Ionis +56% Revenue

The Quick Take

• Coca-Cola raised 2026 guidance after 5% volume growth driven by FIFA World Cup activations and margin expansion.
• Crane Co. posted 26% sales growth and raised its full-year EPS outlook on Aerospace and Advanced Technology strength.
• Ionis Pharmaceuticals reported 56% year-over-year revenue growth driven by strong product sales and pipeline progress.
• Fortrea Holdings faces headwinds from revenue decline and leadership changes, tempering the otherwise broadly positive earnings picture.
• IDEX Corp and BXP Inc also beat expectations, with IDEX citing significant order growth and BXP posting robust leasing results.

A broad sweep of US Q2 2026 earnings reveals predominantly positive results across consumer staples, industrials, healthcare, and real estate. Coca-Cola headlined with a guidance raise after delivering 5% volume growth globally, with FIFA World Cup brand activations proving a meaningful revenue driver beyond expectations. Margin expansion complemented the volume story, reinforcing that KO has successfully navigated the post-COVID cost normalization cycle. Crane Co. added to industrial sector confidence with 26% sales growth and a full-year EPS outlook raise, driven by exceptional Aerospace and Advanced Technology segment performance that aligns with the sustained aircraft production ramp.

In the healthcare and biopharma space, Ionis Pharmaceuticals delivered a standout quarter with 56% year-over-year revenue growth, driven by strong commercial uptake of its approved rare disease and cardiovascular products alongside strategic pipeline milestone payments. Redcare Pharmacy raised its revenue growth guidance and posted improved EBITDA margins, signaling that European digital pharmacy adoption is accelerating beyond pandemic-era tailwinds into structural consumer habit change. The contrasting story came from Fortrea Holdings, which reported a revenue decline and leadership transition — a reminder that the clinical research outsourcing sector is still navigating post-COVID normalization of sponsor trial activity.

For investors watching broad market health, this earnings cluster provides a constructive signal: companies with strong secular demand drivers and operational discipline — consumer marketing scale, defense exposure, biopharma pipeline execution — are raising guidance despite macro uncertainty. BXP Inc's robust leasing results suggest commercial real estate demand is recovering selectively in high-quality urban office and life science clusters. IDEX Corp's significant order growth points to resilient industrial capex from utility and water infrastructure customers. The overall read is a bifurcated market rewarding execution and penalizing sectors facing structural demand headwinds.

Synthesized from 8 sources — full coverage, sentiment breakdown, and forward signals below.